Also trades as: GSK.L (LSE) · $vol 186M · GS7.DE (XETRA) · $vol 2M · GLAXF (OTC) · $vol 0M

$50.94

-0.16 (-0.31%)

After Hours: $51.00 (+0.06, +0.12%)

Weekly Expected Move ±3.6%

$47 $49 $51 $53 $54

NYSE · Healthcare · Drug Manufacturers - General · Tech Score Buy · Power 60 · $102.1B mcap · 1.94B float · 0.210% daily turnover · Short 38% of daily vol

Credit Risk of going bust: lower than 77% of companies Debt: 19.1% of company value Bonds: $161.7M held by 148 funds, 43 bp over Treasuries → details ▾

If the stock fell to about $0.84 (down 98%), GSK plc would be worth roughly what it owes.
Total debt $24.20B against a stock market value of $102.38B.
Distance to default 9.00 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $14.94B (short-term plus half of long-term), stock volatility 26.2%; Altman Z'' 1.49. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$32.0B +1.8% ▲

5Y CAGR: +5.6%

Gross Profit

$23.2B +3.8% ▲

5Y CAGR: +7.1%

Operating Income

$7.0B +74.4% ▲

5Y CAGR: +3.2%

Net Income

$5.6B +117.1% ▲

5Y CAGR: -0.6%

EPS (Diluted)

$2.72 +119.4% ▲

5Y CAGR: -1.0%

EBITDA

$11.6B +74.3% ▲

5Y CAGR: +7.6%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$24.7B	$29.3B	$30.3B	$31.4B	$32.0B
YoY Growth	+1.4%	+18.7%	+3.4%	+3.5%	+1.8%
Cost of Revenue	$8.2B	$9.6B	$8.6B	$9.0B	$8.8B
Gross Profit	$16.5B	$19.8B	$21.8B	$22.3B	$23.2B
Gross Margin	66.9%	67.4%	71.8%	71.2%	72.5%
R&D Expenses	$5.0B	$5.5B	$6.2B	$6.4B	$7.3B
SG&A Expenses	$7.1B	$8.4B	$9.4B	$11.0B	$8.8B
Operating Expenses	$12.2B	$13.3B	$15.0B	$18.3B	$16.2B
Operating Income	$4.4B	$6.4B	$6.7B	$4.0B	$7.0B
Operating Margin	17.6%	21.9%	22.2%	12.8%	21.9%
Interest Expense	$784M	$856M	$775M	$658M	$686M
Income Before Tax	$3.6B	$5.6B	$6.1B	$3.5B	$7.2B
Tax Expense	$83M	$707M	$756M	$526M	$1.1B
Net Income	$4.4B	$15.0B	$4.9B	$2.6B	$5.6B
Net Margin	17.8%	51.0%	16.2%	8.2%	17.5%
EPS (Diluted)	$2.70	$2.40	$2.40	$1.24	$2.72
EBITDA	$6.5B	$8.6B	$9.1B	$6.7B	$11.6B
Shares Outstanding	1.62B	2.04B	2.06B	2.07B	2.06B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$8.0B	$8.1B	$7.5B	$8.0B	$8.5B	$8.6B	$7.6B	$8.4B
Cost of Revenue	$2.4B	$2.6B	$1.9B	$2.2B	$2.3B	$2.7B	$1.9B	$2.3B
Gross Profit	$5.6B	$5.6B	$5.6B	$5.8B	$6.3B	$6.0B	$5.8B	$6.1B
Gross Margin	70.1%	68.5%	74.2%	72.9%	73.6%	69.2%	75.4%	73.1%
R&D Expenses	$1.5B	$2.0B	$1.5B	$2.0B	$1.7B	$2.4B	$1.7B	$3.5B
SG&A Expenses	$3.8B	$2.7B	$2.1B	$2.1B	$2.2B	$2.6B	$2.1B	$2.2B
Operating Expenses	$5.4B	$4.9B	$3.4B	$3.8B	$3.7B	$4.5B	$3.5B	$5.7B
Operating Income	$189M	$696M	$2.2B	$2.0B	$2.6B	$1.5B	$2.3B	$481M
Operating Margin	2.4%	8.6%	29.5%	25.3%	30.3%	17.5%	30.1%	5.7%
Interest Expense	$156M	$144M	$162M	$184M	$167M	$174M	$167M	$182M
Income Before Tax	$64M	$563M	$2.1B	$1.9B	$2.5B	$950M	$2.1B	$354M
Tax Expense	-$1M	$62M	$336M	$241M	$312M	$223M	$305M	-$199M
Net Income	-$58M	$414M	$1.6B	$1.4B	$2.0B	$636M	$1.7B	$435M
Net Margin	-0.7%	5.1%	21.6%	18.1%	23.6%	7.4%	22.8%	5.2%
EPS (Diluted)	$-0.03	$0.20	$0.78	$0.70	$0.98	$0.82	$0.86	$0.22
EBITDA	$1.2B	$1.1B	$3.1B	$3.2B	$3.4B	$1.9B	$2.8B	$761M
Shares Outstanding	2.04B	2.07B	2.07B	2.06B	2.05B	1.02B	2.04B	2.03B

GSK NYSE